Home / Our Pipeline / SLN360

Addressing a Major Unmet Need in Cardiovascular Disease

SLN360 is our wholly owned siRNA (short interfering RNA) in development for high lipoprotein(a), or Lp(a), a genetically determined cardiovascular risk factor affecting around 20% of the world’s population.

About SLN124

SLN360 is a gene ‘silencing’ therapy – one that is designed to temporarily block a specific gene’s message that would otherwise trigger an unwanted effect. In this case, it aims to ‘silence’ LPA, a gene that tells the body to make a specific protein that is only found in Lp(a). By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks and strokes.

Learn More About Cardiovascular Disease Due to High Lp(a)


We are evaluating SLN360 in the global APOLLO Phase 1 clinical program. It aims to assess the safety, tolerability, pharmacodynamic and pharmacokinetic response of SLN360 in people with high Lp(a) levels who are at increased risk of premature heart disease, heart attack or stroke.

Learn More About the APOLLO Study

Lead investigator of the SLN360 APOLLO trial, Steven E. Nissen, M.D., Chief Academic Officer of the Heart, Vascular and Thoracic Institute at Cleveland Clinic, discusses high lipoprotein(a) as a key driver of heart disease and encouraging results observed in the SLN360 phase 1 single-ascending dose study.